The cluster of two top R&D scientists selling simultaneously is unusual and could signal private concern about pipeline progress or upcoming data. Monitor for any near-term clinical trial readouts, regulatory updates, or a Form 8-K disclosing material pipeline changes.
INCY drugs
INCY drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $123.50entry
- T+1 · 3mo ago −0.02%α +0.65% · $123.47
- T+5 · 3mo ago +3.63%α +4.82% · $127.98
- T+20 · 2mo ago −1.43%α +0.55% · $121.74
- T+60 · 7d ago −2.59%α +0.35% · $120.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top R&D executives at Incyte sold a combined $1.57M in stock over a 7-day window. President Pablo Cagnoni sold $1.30M and CSO Patrick Mayes sold $274K. While the dollar amount is modest relative to Incyte's $24.4B market cap (~0.006%), the cluster of two senior scientific officers selling within days of each other warrants attention, especially given the company's heavy reliance on pipeline catalysts.
Key Financial Metrics
Key Facts
- President & Global Head of R&D Pablo Cagnoni sold 10,803 shares at $120.04 for $1.30M on 2026-08-12
- EVP & Chief Scientific Officer Patrick Mayes sold 2,200 shares at $123.99 for $274K on 2026-08-05
- Total insider selling in cluster: $1.57M, representing ~0.006% of $24.4B market cap
- Both sellers are senior R&D executives, not routine diversifiers (e.g., directors or 10% owners)
- No open-market insider purchases occurred in the cluster window
Financial Impact
$1.57M in insider sales, negligible relative to $24.4B market cap
Risk Factors
- Sales may be pre-arranged 10b5-1 plans or routine diversification, not necessarily bearish
- No Form 4 filing details provided to confirm plan status or vesting schedules
- Incyte's analyst consensus is 52% bullish, suggesting market sentiment may diverge from insider behavior
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-INCY-1786774564279 |
Track record
18 reports on INCY
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $118.50 Now $120.97 +2.08% settles Feb 16
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $123.09 Now $120.97 −1.72% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $119.45 Now $120.97 +1.27% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $120.97 Now $120.97 +0.00% settles Feb 11
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $122.27 Now $120.97 −1.06% settles Feb 9
- Nov 6, 202610d ago 144 Neutral 4/10 Entry $121.89 Now $120.97 −0.75% settles Feb 5
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $122.85 Now $120.97 −1.53% settles Feb 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $116.80 Now $120.97 +3.57% settles Jan 27
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $115.71 Now $120.97 +4.55% settles Jan 21
- Aug 14, 202613w ago Insider Cluster Bearish 4/10 Viewing Entry $123.50 to $120.30 Now $120.97 +2.05% ▲ +2.59% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers